JNCI Journal of the National Cancer Institute 2014-08-01

Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.

Sharon M Castellino, Nicole J Ullrich, Megan J Whelen, Beverly J Lange

Index: J. Natl. Cancer Inst. 106(8) , doi:10.1093/jnci/dju186, (2014)

Full Text: HTML

Abstract

Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck. Risk factors for cancer-related cognitive dysfunction include young age at diagnosis, treatment with cranial irradiation, use of parenteral or intrathecal methotrexate, female sex, and pre-existing comorbidities. Limiting use and reducing doses and volume of cranial irradiation while intensifying chemotherapy have improved survival and reduced the severity of cognitive dysfunction, especially in leukemia. Nonetheless, problems in core functional domains of attention, processing speed, working memory and visual-motor integration continue to compromise quality of life and performance. We review the epidemiology, pathophysiology and assessment of cancer-related cognitive dysfunction, the impact of treatment changes for prevention, and the broad strategies for educational and pharmacological interventions to remediate established cognitive dysfunction following childhood cancer. The increased years of life saved after childhood cancer warrants continued study toward the prevention and remediation of cancer-related cognitive dysfunction, using uniform assessments anchored in functional outcomes. © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.


Related Compounds

Related Articles:

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.

2014-08-26

[Br. J. Cancer 111(5) , 874-82, (2014)]

Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells.

2015-01-01

[MAbs 7(2) , 403-12, (2015)]

TLR signaling modulates side effects of anticancer therapy in the small intestine.

2015-02-15

[J. Immunol. 194(4) , 1983-95, (2015)]

Chemometrics-assisted Spectrofluorimetric Determination of Two Co-administered Drugs of Major Interaction, Methotrexate and Aspirin, in Human Urine Following Acid-induced Hydrolysis.

2015-01-01

[Comb. Chem. High Throughput Screen 18 , 723-34, (2015)]

Prediction of methotrexate CNS distribution in different species - influence of disease conditions.

2014-06-16

[Eur. J. Pharm. Sci. 57 , 11-24, (2014)]

More Articles...